What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on
Last year the M&A spotlight in biopharma centered on big money and some large appetites for pipeline and portfolio restructuring. This year is all about bolt-ons and the careful devouring of new pipeline assets.
A few weeks ago we asked the incomparable Chris Dokomajilar, who heads DealForma, to run a cut of the numbers on all the biotech M&A deals of any consequence for 2020. Below, you’ll find everything above the $50 million low-water mark.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.